In a surprising social media post, Trump asserts he can cancel all executive orders not directly signed by him, citing Biden's use of the autopen. Legal experts weigh in on the legitimacy of his claims.
In response to the tragic shooting of two National Guard members, President Trump has announced a controversial plan to 'permanently pause migration' from certain countries, targeting what he describes as 'Third World Countries.' This move raises questions about his administration's immigration policies and national security stance.
In a dramatic move, President Trump announced the cancellation of all executive orders signed by Biden via autopen, claiming illegality in the process. This decision raises questions about Biden's presidency and Trump's power play.
Donald Trump has announced plans to cancel many of Joe Biden's executive orders, claiming they were signed without Biden's knowledge using an autopen. Is this a valid concern or just political rhetoric?
In a significant move, the Trump administration is reexamining all green cards issued to individuals from 19 countries deemed a concern, following a shooting incident involving two National Guard members. This action intensifies the ongoing immigration crackdown.
In a shocking ambush near the White House, an Afghan national named Rahmanullah Lakanwal is identified as the shooter who wounded two National Guard troops. The suspect, currently hospitalized, is not cooperating with authorities.
In a surprising move, Marjorie Taylor Greene announces her resignation from Congress, sparking speculation about her political future amidst a fallout with Trump. Could a 2028 presidential bid be in the cards?
In a bid for transparency, top Trump officials are meeting to discuss the release of Justice Department files on Jeffrey Epstein, amidst a divided Republican Party. Will the truth finally come out?
In a controversial Veterans Day speech, Trump declared his commitment to renaming the holiday and emphasized the U.S. military's strength, sparking discussions on political correctness and military strategy.
Despite losing a $10 billion bid for Metsera to Pfizer, Novo Nordisk's CEO Mike Doustdar remains determined to pursue new opportunities in the obesity and diabetes sectors. The company aims to reclaim its position in the booming weight-loss market.